Route of Administration:
IMFINZI is a Cancer drug manufactured by Astrazeneca and administered via the Intravenous route of administration. The J Code: J9173 is aligned to the drug IMFINZI.
Imfinzi works by blocking a protein on the surface of cancer cells called PD-L1. Imfinzi is administered via intravenous infusion over a one-hour time frame. Imfinzi was previously aligned to the temporary HCPCS C9492 before receiving the permanent HCPCS J9173. Patient support for this medication can be found through Astrazeneca Pharmaceuticals AZ & Me prescription savings program here: https://www.azandmeapp.com/prescriptionsavings/. Additionally, patient support for Imfinzi can be found here: https://www.myaccess360.com/imfinzi-durvalumab.html.